STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRVO
  4. [Form 4] CervoMed Inc. Insider Trading Activity

CervoMed insider boosts holdings to 12,500 CRVO shares

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) reported insider share purchases by a senior executive. The company’s CFO, General Counsel and Secretary bought 1,000 shares of common stock on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share in open‑market transactions. Following these transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.

The filing notes that the 2,500 shares purchased on 11/18/2025 were acquired at prices ranging from $8.26 to $8.38, with the weighted average price reported, and that detailed trade breakdowns are available upon request.

Positive

  • None.

Negative

  • None.
Insider ELDER WILLIAM ROBERT
Role CFO, GC & Secretary
Bought 3,500 shs ($29K)
Type Security Shares Price Value
Purchase Common Stock 2,500 $8.32 $21K
Purchase Common Stock 1,000 $8.45 $8K
Holdings After Transaction: Common Stock — 12,500 shares (Direct)
Footnotes (1)
  1. Shares purchased in open-market transactions. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.26 to $8.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ELDER WILLIAM ROBERT
(Last) (First) (Middle)
20 PARK PLAZA, SUITE 424
(Street)
BOSTON MA 02116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO, GC & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/17/2025 P 1,000(1) A $8.45 10,000 D
Common Stock 11/18/2025 P 2,500(1) A $8.32(2) 12,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares purchased in open-market transactions.
2. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.26 to $8.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.
/s/ William R. Elder 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CervoMed Inc. (CRVO) disclose in this Form 4?

CervoMed Inc. disclosed that its CFO, General Counsel and Secretary purchased shares of the company’s common stock in open‑market transactions on 11/17/2025 and 11/18/2025.

How many CervoMed (CRVO) shares did the executive buy and at what prices?

The executive bought 1,000 shares on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share.

How many CervoMed (CRVO) shares does the reporting person own after these trades?

After the reported transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.

What price range was used to calculate the weighted average price on 11/18/2025 for CRVO?

The 2,500 shares purchased on 11/18/2025 were bought at prices ranging from $8.26 to $8.38 per share, resulting in a weighted average price of $8.32.

Were the CervoMed (CRVO) insider share purchases open‑market transactions?

Yes. The filing states that the reported shares were purchased in open‑market transactions.

Who is the reporting person in this CervoMed (CRVO) Form 4 filing?

The reporting person is an officer of CervoMed Inc., serving as CFO, General Counsel and Secretary.